Navigation Links
Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
Date:3/13/2008

re were no drug-related serious adverse events and no adverse events were considered to be definitely or probably related to study treatment. In the multiple ascending dose studies all possibly-related adverse events were mild in severity and resolved spontaneously.

"We're very encouraged with the results of the ex vivo response study that suggest a majority of Pompe patients may be treatable with our pharmacological chaperone AT2220," said John F. Crowley, President and CEO of Amicus Therapeutics. "Based on these data and the safety data from the Phase 1 studies, we look forward to commencing a Phase 2 clinical trial in Pompe patients the first half of this year."

As of November 2007, AT2220 is being developed in partnership with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, which is focused on genetic diseases.

About Pompe Disease

Pompe disease affects an estimated 5,000-10,000 patients worldwide and is clinically heterogeneous in the age of onset, the extent of organ involvement, and the rate of progression. The early onset form of the disease is the most severe, progresses most rapidly, and is characterized by musculoskeletal, pulmonary, gastrointestinal, and cardiac symptoms that usually lead to death from cardio-respiratory failure between 1 and 2 years of age. The late onset form of the disease begins between childhood and adulthood and has a slower rate of progression that is characterized by musculoskeletal and pulmonary symptoms that usually lead to progressive weakness and respiratory insufficiency. A high majority of patients have the late onset form of the disease. The U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for the active ingredient in AT2220 in the United States.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the tre
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
2. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
6. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
7. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
8. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
9. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
10. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
11. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 2015   Prime Therapeutics LLC (Prime), a ... members, today released the following statement responding to the ... first biosimilar to enter the U.S. market. ... of Sandoz,s Zarxio® to treat neutropenia, a condition affecting ... milestone in our country,s journey to curb the escalating ...
(Date:3/6/2015)... Solutions, Inc. (Pink Sheets: ASDS ) ("Ascendant" ... fourth quarter and year ended December 31, 2014. The ... than $0.01 per share, on revenues of $8,018,000 for ... net income of $195,000, or $0.01 per share, on ... The substantial increase in fourth quarter 2014 revenue was ...
(Date:3/6/2015)... TAMPA, Fla. , March 6, 2015 /PRNewswire/ ... received special validation from Intuitive Surgical, the manufacturer ... for their Triton-36 Instrument Cleaning System. This approval ... highest standards in cleanliness currently in place for ... this special validation for reprocessing robotic surgical instruments ...
Breaking Medicine Technology:Prime Therapeutics welcomes FDA's approval of first biosimilar in U.S., but says more clarity is needed 2Prime Therapeutics welcomes FDA's approval of first biosimilar in U.S., but says more clarity is needed 3Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 2Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 3Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 4Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 5Ultra Clean Systems Reaches Exclusive Place within Robotic Surgical Instrument Cleaning Industry with Latest Certifications 2
... Inc. (Nasdaq: ENZN) announced today that four,posters containing ... Meeting of the American Association for Cancer Research,(AACR) ... 2007 in Los Angeles, CA., Details of the ... EZN-2208, a novel polyethyleneglycol-SN38,conjugate, has potent antitumor activity ...
... 13, 2007 - Point Therapeutics, Inc.,(NASDAQ: POTP) today ... 2007 Annual Meeting of the American,Association for Cancer ... 14-18, 2007. The AACR poster presentations report,on preclinical ... details for the AACR presentations are as,follows: , ...
Cached Medicine Technology:Enzon to Present Preclinical Data From PEG-SN38 and PEGylation,Technology Studies at AACR Meeting 2
(Date:3/6/2015)... 06, 2015 Follow us on ... most common forms of cancer and is the leading ... be screened through various techniques and tools, including mammography, ... the gold standard technique in breast cancer screening, driven ... taken for the procedure, required expertise to carry out ...
(Date:3/6/2015)... “On Tap” takes the audience on a journey ... the silver screen and to modern day rhythm tap. ... their famous eye-high kicks! Producers, directors and choreographers Mary Six ... dancing in this robust show, showcasing one of the only ... , “On Tap” is proud to host guest stars ...
(Date:3/6/2015)... 2015 As the Association of ... of 90,000 doctors by 2025 is updated this week ... (SH) is proactively preparing by analyzing demographics and pursuing ... , Several factors including the increasing number of ... under the Affordable Care Act and an uneven distribution ...
(Date:3/6/2015)... 2015 Jvion, the Atlanta-based leader ... a Clostridium Difficile (C Diff) predictive use case ... use case is the latest in a broad ... infections, chronic conditions, and individual illnesses. Using the ... solution flags at risk individuals to help support ...
(Date:3/6/2015)... Yisrayl Hawkins, Pastor and Overseer of ... a new publication explaining how micro-kingdoms keep the earth ... article titled “Microorganisms Do Much More Than You Think” ... were created and designed to keep all things functioning ... the functions of these micro-kingdom, but does not realize ...
Breaking Medicine News(10 mins):Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 2Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 3Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 4Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2Health News:Yisrayl Hawkins Tells Scientists Exactly What Makes Life Function Properly in New Publication 2
... which is angered by the defence attorneys of the AIIMS ... about the case where a boy, suffering from cancer, got ... 2001. ,The victim, who was nine years ... in July 2000 for treatment of cancer, supposedly has contracted ...
... the Human Fertilization and Embryology Authority show that recently ... opting for assisted reproduction technology// (ART) in the UK. ... of these women is 34. There is increase in ... for infertility. The doctors and scientists say that there ...
... new study, the antidepressant drug Zoloft (sertraline) may avoid ... also increase// the time interval between the depressive episodes. ... to background information in the study, reports foodconsumer.org. ... of age, who had recovered from depression during treatment ...
... the UK have been busy. They have tolled up 100,000 ... stop and control the spread of bird flu.// Researchers eleven ... they screened possible drug components that could be effective against ... the UK was originally built to help particle physicists examine ...
... A recent conducted at University of Michigan Health Systems ... have greater expectations of doom from their screening //mammography ... than not these expectations were unusually high or unrealistic. ... to an outpatient clinic for screening mammography. The participants ...
... the oldest mother in UK, from Lewes in East Sussex, ... fertility treatment. She gave the statement that this child had ... John Farrant made a joint statement, "We wish to emphasise ... without courage. A great deal of thought has been given ...
Cached Medicine News:Health News:A Boy Undergoing Treatment For Cancer Gets AIDS At AIIMS 2Health News:UK Computer Grid In Bird Flu Fight 2Health News:UK Computer Grid In Bird Flu Fight 3Health News:Most Women Have Unrealistic Expectations From Screening Mammography 2Health News:A mother at 63: oldest in UK! 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... Products are kept in ... are offered as 1-piece ... or extra long lengths. ... insulation, flush ports, rotating ...
... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
Medicine Products: